Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
- Lancet Oncol., Oct 19 2023, S1470-2045(23)00515-6 | https://doi.org/10.1016/S1470-2045(23)00515-6